Request Clinical Starter Kits for Your Patients Today! Request Now

Are you a clinician?

This is a clinician-only website.
By entering, you acknowledge that you're a clinician.

ENDUR-ACIN® improves blood lipids and transfer proteins in patients with hyperlipidemia, study shows


  • ENDUR-ACIN® significantly improves blood lipids in patients with hyperlipidemia
  • Effective dosage is 1,500 to 2,000 mg/day
  • Significant improvements in blood lipids and transfer proteins reported
  • Low 5% dropout rate due to treatment intolerance


This randomized, double-blind, placebo-controlled, cross-over trial was designed to investigate the efficacy of ENDUR-ACIN® wax matrix niacin on lipid transport systems in patients with hyperlipidemia.

For this 6-month study, researchers followed 69 patients, aged 20-69 years, with total cholesterol levels between 225-300 mg/dl after 2 months of diet therapy. Participants were randomized into two groups. One group (n = 39) took ENDUR-ACIN® (2 months), placebo (2 months), then ENDUR-ACIN® (2 months). The other group (n = 30) took placebo (2 months), ENDUR-ACIN® (2 months), then ENDUR-ACIN® (2 months). The daily ENDUR-ACIN® dosage was 1,500 mg to 2,000 mg.

Results indicate ENDUR-ACIN® significantly reduced total cholesterol, low-density (LDL) lipoprotein cholesterol, and triglyceride levels and significantly increased high-density lipoprotein (HDL) cholesterol. Apolipoprotein A-I and apolipoprotein B levels significantly improved. Treatment also decreased plasma cholesterol ester transfer protein (CETP) activity and increased cholesterol-esterifying capacity (see Table 1).  A 5% dropout rate was reported related to treatment intolerance.


Table 1.  Changes in Blood Lipid Parameters with ENDUR-ACIN® Treatment
Parameter EPE Group PEE Group
Total Cholesterol -12% -11%
LDL Cholesterol -18% -16%
HDL Cholesterol +14% +13%
Triglycerides -17% -20%
Apo-A-I +16% +11%
Apo-B -22% -20%
Plasma CETP activity -17% -14%
Cholesterol-esterifying Capacity +33% +64%
EPE indicates ENDUR-ACIN, placebo, ENDUR-ACIN treatment sequence; PEE, placebo, ENDUR-ACIN, ENDUR-ACIN treatment sequence, LDL, low-density lipoprotein, HDL, high-density lipoprotein, Apo-B, apolipoprotein B, Apo-A-I, apolipoprotein A-I, CETP, cholesterol ester transfer protein.


These findings indicate that ENDUR-ACIN® is an effective, well-tolerated treatment for correcting disturbances in lipid transport systems in patient with hyperlipidemia.


Oganov RD, Perova NV, Kiseleva NG, Olferiev AM, et al. Beneficial effects of wax-matrix sustained-release niacin on lipid-transport system in patients with hypercholesterolemia. In: Proceedings of the 10th International Symposium on Atherosclerosis, Montreal, October 9-14, 1998; Montreal, Canada. Abstract 158.